Jacobs Levy Equity Management
AGRX

Jacobs Levy Equity Management’s Agile Therapeutics AGRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16
Closed -$15K – 1100
2018
Q2 		$15K Hold
16
– – ﹤0.01% 1012
2018
Q1 		$80K Hold
16
– – ﹤0.01% 972
2017
Q4 		$86K Buy
+16
New +$149K ﹤0.01% 957

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jacobs Levy Equity Management's AGRX Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of Agile Therapeutics (AGRX) in Q3 2018, closing a stake of 16 shares — an estimated $15K sold.

Jacobs Levy Equity Management first reported a position in AGRX in Q4 2017 and held it in 3 quarters. The position peaked at $86K in Q4 2017. 29 funds tracked by Wall St. Rank hold AGRX as of Q3 2018.

  • Jacobs Levy Equity Management reported no remaining Agile Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 16 Agile Therapeutics shares in Q3 2018, an estimated $15K.
  • Jacobs Levy Equity Management first reported a position in Agile Therapeutics in Q4 2017 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Agile Therapeutics position peaked at $86K in Q4 2017.
  • 29 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.